Clinical Trials Logo

Filter by:
NCT ID: NCT02878863 Withdrawn - Clinical trials for Hepatitis, Autoimmune

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

Start date: August 2016
Phase: Phase 3
Study type: Interventional

An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.

NCT ID: NCT02870855 Withdrawn - Infertility Clinical Trials

Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients

Start date: July 28, 2017
Phase: N/A
Study type: Interventional

Repeated implantation failure(RIF) is a insurmountable bottleneck in assisted reproductive technology, many studies have considered that the cause of two-thirds of implant failure is the decreased endometrial receptivity. Human chorionic gonadotropin (hCG) is an early pre-plant signal molecule secreted by the embryo, it can promote endometrial proliferation, increase blood flow and promote embryonic adhesion and inhibit self-regulate apoptosis of trophoblast cells. Previous studies showed that: intrauterine injection of HCG before embryo transfer can improve clinical outcomes in IVF/Intracytoplasmic sperm injection(ICSI). But some studies found that the intrauterine injection of HCG can not significantly improve the success rate of blastocyst transfer, and the reason may be the intrauterine injection of HCG time is too late to significantly increase the implantation rate. Would ahead of intrauterine injection of HCG be more effective? Thus, the patients of repeated implantation frozen embryo cycle according to the random principle accepted two kinds of transplants ways: ①intrauterine injection of HCG before blastocyst transfer; ②blastocyst transfer. Try to understand whether intrauterine injection of HCG can significantly improve the clinical pregnancy rate of blastocyst transfer in repeated implantation failure patients.

NCT ID: NCT02867345 Withdrawn - Clinical trials for Hormone Refractory Prostate Cancer

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Start date: November 2016
Phase:
Study type: Observational

This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.

NCT ID: NCT02863913 Withdrawn - Clinical trials for Invasive Bladder Cancer Stage IV

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced bladder cancer. Blood samples will also be collected for research purposes.

NCT ID: NCT02840227 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections

Start date: December 2013
Phase: N/A
Study type: Interventional

The primary hypothesis is that disease-free survival is improved in patients undergoing resection for tumor thought to be stage I-III primary non-small cell lung cancer in patients with combined general-epidural anesthesia & analgesia as compared to patients receiving general anesthesia and postoperative patient-controlled opioid analgesia. Patients having surgery for resection of potentially curable lung cancer will be randomized to combined general and epidural anesthesia or general anesthesia with opioid analgesia. The primary outcome will be disease-free survival.

NCT ID: NCT02786563 Withdrawn - Clinical trials for Rheumatoid Arthritis (RA)

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Start date: September 30, 2018
Phase:
Study type: Observational

Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring system, and validate the applicability of different simplified US joint scoring systems.

NCT ID: NCT02769494 Withdrawn - Crohn's Disease Clinical Trials

The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer

Start date: March 2016
Phase: Phase 3
Study type: Interventional

This study aims at evaluating efficacy and safety of topical using Mesalazine Sustained-Release Tablets in in the treatment of oral ulcers in patients with Crohn's disease.

NCT ID: NCT02754960 Withdrawn - Clinical trials for Gastrointestinal Hemorrhage

Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding

Start date: March 2010
Phase: Phase 2
Study type: Interventional

Background: Repeated bleeding from gastrointestinal vascular malformations remains to be a major therapeutic challenge. Methods: The investigators performed a randomised, double-blind, placebo-controlled, single centre study to assess the long-term efficacy and safety of thalidomide 100mg qn p.o. or placebo 100 mg qn p.o. administration for 4 months in subjects with recurrent gastrointestinal bleeding due to vascular malformations. Patients with at least six episodes of bleeding in the prior year due to vascular malformation were randomly grouped, prescribed a four-month regimen of either 100mg of thalidomide or 100 mg of placebo orally one time daily, and monitored for at least one year. The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. Secondary outcomes included the changes from baseline in participants dependent on blood transfusions and transfused packed red cell units, bleeding episodes, bleeding durations, and hemoglobin levels at 12 months. Statistical significance was defined at P < 0.05.

NCT ID: NCT02736552 Withdrawn - Gastric Cancer Clinical Trials

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Start date: March 2016
Phase: Phase 3
Study type: Interventional

The study aims to compare the efficacy and safety of S-1 for 6 months versus S-1 for 1 year as adjuvant chemotherapy after D2 resection in patients with gastric cancer. Hypothesis: For gastric patients after D2 resection, S-1 for 6 months shows non-inferiority to S-1 for 1 year in disease free survival(DFS), overall survival (OS) and safety.

NCT ID: NCT02723942 Withdrawn - Clinical trials for CAR-T Cell Immunotherapy

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma.